Published in Circ Res on March 07, 2016
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events | NCT00239681
GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circ Res (2016) 0.83
Glycosylation Signatures of Inflammation Identify Cardiovascular Risk: Some Glyc It Hot. Circ Res (2016) 0.75
Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem (2017) 0.75
Differential Associations of Inflammatory Markers With Insulin Sensitivity and Secretion: The Prospective METSIM Study. J Clin Endocrinol Metab (2017) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Glycosylation in cellular mechanisms of health and disease. Cell (2006) 8.45
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA (2006) 2.99
Glycomics hits the big time. Cell (2010) 2.56
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med (2013) 2.33
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem (2009) 2.31
GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clin Chem (2015) 1.95
Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics (2008) 1.94
Glycosylation in immune cell trafficking. Immunol Rev (2009) 1.61
Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med (2014) 1.60
O-GlcNAc signaling in the cardiovascular system. Circ Res (2010) 1.43
Glycosylation of serum proteins in inflammatory diseases. Dis Markers (2008) 1.39
Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett (1987) 1.24
Value of an Endpoints Committee versus the use of nosologists for validating cause of death. Contemp Clin Trials (2006) 1.23
A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc (2014) 1.13
The role of chronic inflammation in obesity-associated cancers. ISRN Oncol (2013) 1.04
Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol (2014) 1.02
Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol (2015) 0.97
The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nat Chem Biol (2014) 0.93
Serum Nuclear Magnetic Resonance Spectroscopy: One More Step toward Clinical Utility. Clin Chem (2015) 0.89
A glycomics approach to the discovery of potential cancer biomarkers. Methods Mol Biol (2010) 0.89
Cotranslational and posttranslocational N-glycosylation of proteins in the endoplasmic reticulum. Semin Cell Dev Biol (2014) 0.87
A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Glycosyltransferases, glycosylation and atherosclerosis. Glycoconj J (2014) 0.80